TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10367994

Group type: EXPERIMENTAL
Intervention: MMPI scales Pa, Sc and validity scale F
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MMPI scales Hs, D, and Hy
Number of subjects: 19

Group type: COMPARATOR
Intervention: MMPI scales Hs, D and Hy in clinical remission
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MMPI scales Pd and Pt
Number of subjects: 19

Group type: COMPARATOR
Intervention: MMPI scores in remission
Number of subjects: 19
Study: 7585856

Group type: EXPERIMENTAL
Intervention: Intervention letters sent to physicians
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (physicians who did not receive letters)
Number of subjects: 190
Study: 1969684

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg bid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg bid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 495537

Group type: EXPERIMENTAL
Intervention: Sucrose diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Starch diet
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 19
Study: 31290569

Group type: EXPERIMENTAL
Intervention: R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 90 Y-ibritumomab tiuxetan
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine)
Number of subjects: 62
Study: 28400132

Group type: EXPERIMENTAL
Intervention: Lighting device (flashes at 100 cycles per minute)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No lighting device (control)
Number of subjects: 22
Study: 25533307

Group type: EXPERIMENTAL
Intervention: Close Rectal Dissection (CRD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Total Mesorectal Excision (TME)
Number of subjects: 59
Study: 23658423

Group type: EXPERIMENTAL
Intervention: 0.45 g/d 20:5n3 and 22:6n3 (1.51:1)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 0.9 g/d 20:5n3 and 22:6n3 (1.51:1)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 1.8 g/d 20:5n3 and 22:6n3 (1.51:1)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 21874260

Group type: EXPERIMENTAL
Intervention: Combination of branched-chain amino acids (BCAA; 12 g/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCAA (12 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE-I (perindopril; 4 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 0
Study: 19619146

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 93
Study: 16950506

Group type: EXPERIMENTAL
Intervention: In vivo axial
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: In vivo gingival
Number of subjects: 5

Group type: COMPARATOR
Intervention: In vitro axial
Number of subjects: 5

Group type: COMPARATOR
Intervention: In vitro gingival
Number of subjects: 5
Study: 15257378

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g per day for 2 or 3 weeks
Number of subjects: 101
Study: 12716812

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg o.d.)
Number of subjects: 54
Study: 9988834

Group type: EXPERIMENTAL
Intervention: Estrostep (20 microg ethinyl estradiol on days 1-5, 30 microg on days 6-12, 35 microg on days 13-21, and 1 mg norethindrone acetate throughout the cycle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30-microg ethinyl estradiol monophasic control drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrostep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triphasic control drug
Number of subjects: 0
Study: 7483113

Group type: EXPERIMENTAL
Intervention: Tablets containing 66 mg ferrous iron (as fumarate) daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 2317425

Group type: EXPERIMENTAL
Intervention: Humidified gas
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-humidified gas
Number of subjects: 42
Study: 7191315

Group type: EXPERIMENTAL
Intervention: Acemetacin (90 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tolmetin (600 mg daily)
Number of subjects: 40
Study: 31915064

Group type: EXPERIMENTAL
Intervention: Morita therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 16
Study: 30203308

Group type: EXPERIMENTAL
Intervention: Enhanced version of parent-implemented Early Start Denver Model (P-ESDM) with motivational interviewing, multimodal learning tools, and weekly 1.5-h home visits for 12 weeks.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Basic model of parent-implemented Early Start Denver Model (P-ESDM) with 1.5 h of clinic-based parent coaching weekly for 12 weeks.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both enhanced and basic models of P-ESDM.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Enhanced version of P-ESDM.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Basic version of P-ESDM.
Number of subjects: 45
Study: 25156040

Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene (10 mg day(-1)) and vitamin C (500 mg day(-1))
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (50 mg day(-1) of vitamin C)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene and vitamin C
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24504008

Group type: EXPERIMENTAL
Intervention: Educational intervention of home visitors in municipalities with high bonding social capital
Number of subjects: 4034

Group type: EXPERIMENTAL
Intervention: Educational intervention of home visitors in municipalities with high linking social capital
Number of subjects: 4034
Study: 22616927

Group type: EXPERIMENTAL
Intervention: 10% Carbamide Peroxide (CP) home-use
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20% Carbamide Peroxide (CP) home-use
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 38% Hydrogen Peroxide (HP) in-office
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 35% Hydrogen Peroxide (HP) in-office
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 100
Study: 19398325

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard outpatient clinic follow-up
Number of subjects: 109
Study: 17558825

Group type: EXPERIMENTAL
Intervention: History of depression
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: No history of depression
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Depression history and depression-related measures
Number of subjects: 677

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 677
Study: 14759618

Group type: EXPERIMENTAL
Intervention: Hormonal emergency contraception
Number of subjects: 0
Study: 11352955

Group type: EXPERIMENTAL
Intervention: HD-MVAC (high-dose-intensity chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin plus granulocyte colony-stimulating factor)
Number of subjects: 263

Group type: COMPARATOR
Intervention: MVAC (classic chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: HD-MVAC
Number of subjects: 263

Group type: COMPARATOR
Intervention: MVAC
Number of subjects: 263
Study: 9679720

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 6
Study: 8004882

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nisoldipine and Propranolol (10 mg twice daily and 80 mg twice daily respectively)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nisoldipine and Propranolol
Number of subjects: 12
Study: 31542406

Group type: EXPERIMENTAL
Intervention: SPF 100+ sunscreen
Number of subjects: 55

Group type: COMPARATOR
Intervention: SPF 50+ sunscreen
Number of subjects: 55
Study: 30891981

Group type: EXPERIMENTAL
Intervention: Ulinastatin intervention group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 27484048

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Glucocorticoids (GC)
Number of subjects: 174
Study: 26068086

Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 23815766

Group type: EXPERIMENTAL
Intervention: High knowledge and poor self-care
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Knowledge, depressive symptoms, and perceived control
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Knowledge and anxiety interaction
Number of subjects: 612
Study: 23097272

Group type: EXPERIMENTAL
Intervention: Iron (50 mg) plus DHA/EPA (420/80 mg)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Iron plus placebo
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Placebo plus a mixture of DHA and EPA (DHA/EPA)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 321
Study: 19398079

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3965

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3965
Study: 16960468

Group type: EXPERIMENTAL
Intervention: 60 mg dapoxetine
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: 60 mg dapoxetine and 20 mg paroxetine
Number of subjects: 340
Study: 14742620

Group type: EXPERIMENTAL
Intervention: Selective amygdalo-hippocampectomy (SAH) using sylvian approach (9 left/10 right) or transcortical approach (5 left/10 right)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Selective amygdalo-hippocampectomy (SAH)
Number of subjects: 34
Study: 11751735

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 10
Study: 9425966

Group type: EXPERIMENTAL
Intervention: Subarachnoid sufentanil (12.5 microg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Subarachnoid lidocaine (75 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Subarachnoid sufentanil (12.5 microg) in women
Number of subjects: 39

Group type: COMPARATOR
Intervention: Subarachnoid lidocaine (75 mg) in women
Number of subjects: 39
Study: 8236030

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Needles with a diameter of 25G
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Needles with a diameter of 23G
Number of subjects: 11
Study: 3442979

Group type: EXPERIMENTAL
Intervention: Cervical dilatation during IUD insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cervical dilatation during IUD insertion
Number of subjects: 0
Study: 30658379

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) applied for 1 minute
Number of subjects: 30

Group type: COMPARATOR
Intervention: 37% phosphoric acid etch followed by bonding
Number of subjects: 30
Study: 27639604

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5mg weekly for three months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study: 24744165

Group type: EXPERIMENTAL
Intervention: Profiling Ca²⁺ (Pd(Ca))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low constant dialysate Ca²⁺ (Ld(Ca), 1.25 mM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: High constant dialysate Ca²⁺ (Hd(Ca), 2 mM)
Number of subjects: 22
Study: 21557796

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B‐TURP)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M‐TURP)
Number of subjects: 279
Study: 20067426

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Anthelminthic treatment
Number of subjects: 2507
Study: 18717802

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg x kg(‐1) over 20 min followed by an infusion of 0.5 microg x kg(‐1) x h(‐1)) as an adjunct to TIVA (propofol and remifentanil)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg x kg(‐1) over 20 min followed by an infusion of 0.5 microg x kg(‐1) x h(‐1))
Number of subjects: 9
Study: 16463843

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Microdialysis
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Correlation with rCMRglc
Number of subjects: 11
Study: 12756022

Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desferrioxamine (DFX)
Number of subjects: 0
Study: 10343216

Group type: EXPERIMENTAL
Intervention: 0.5 mg hyoscyamine sulfate intravenous (n = 57)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (n = 59)
Number of subjects: 116
Study: 7473013

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (S)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Scaling and root planing with tetracycline (TC) fiber (SF)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Single application of TC fiber (F)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Two serial applications of TC fiber (FF)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Baseline detection of pathogens: 70.8% Fn, 42.9% Pg, 63.5% Pi, 29.7% Ec, 28.3% Cr, 5.5% Aa.
Number of subjects: 116
Study: 1775607

Group type: EXPERIMENTAL
Intervention: Imipramine added to fluphenazine decanoate and benztropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6946109

Group type: EXPERIMENTAL
Intervention: 0.243% NaF dentifrice
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.40% SnF2 dentifrice
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo dentifrice (non-fluoride)
Number of subjects: 11
Study: 31778428

Group type: EXPERIMENTAL
Intervention: Pharmacist-led discharge counseling
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no pharmacist-led counseling)
Number of subjects: 66
Study: 29462011

Group type: EXPERIMENTAL
Intervention: PEEP 7 or 9 cm H2O (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zero PEEP (n = 12)
Number of subjects: 24
Study: 26850449

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study: 24643000

Group type: EXPERIMENTAL
Intervention: Endovascular recanalization (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conservative management (group B)
Number of subjects: 40
Study: 22146757

Group type: EXPERIMENTAL
Intervention: Upstream use of clotinab with 600-mg clopidogrel pretreatment
Number of subjects: 786

Group type: COMPARATOR
Intervention: Provisional use of clotinab with 600-mg clopidogrel pretreatment
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Upstream use of clotinab
Number of subjects: 786

Group type: COMPARATOR
Intervention: Provisional use of clotinab
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Upstream use of clotinab in high-risk population (Killip class ≥II or GRACE score >140)
Number of subjects: 786
Study: 20648601

Group type: EXPERIMENTAL
Intervention: Direct switch to adefovir (ADV)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Overlap of LAM and ADV for 3 months followed by ADV monotherapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 17466071

Group type: EXPERIMENTAL
Intervention: Topical honey along with intralesional injection of glucantime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intralesional injection of glucantime alone
Number of subjects: 100
Study: 14964629

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% applied twice daily with overnight occlusion
Number of subjects: 294

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 294
Study: 11313170

Group type: EXPERIMENTAL
Intervention: L-758,298 (60 or 100 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ondansetron (32 mg)
Number of subjects: 53
Study: 9390601

Group type: EXPERIMENTAL
Intervention: Alfentanil 70 microg/kg over 10 min before surgical incision
Number of subjects: 38

Group type: COMPARATOR
Intervention: Alfentanil 70 microg/kg over 10 min after incision
Number of subjects: 38
Study: 8198929

Group type: EXPERIMENTAL
Intervention: Locally applied morphine at 100 ng ml‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locally applied morphine at 100 micrograms ml‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3332675

Group type: EXPERIMENTAL
Intervention: Acyclovir 3% ointment and vidarabine 3% ointment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Acyclovir 3% ointment and placebo
Number of subjects: 32
Study: 31980993

Group type: COMPARATOR
Intervention: Dapivirine vaginal ring
Number of subjects: 0

Group type: COMPARATOR
Intervention: External peers
Number of subjects: 0
Study: 29555393

Group type: EXPERIMENTAL
Intervention: Cytokine measurements on days 1, 3, and 5
Number of subjects: 181
Study: 26744232

Group type: EXPERIMENTAL
Intervention: smartcare
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: smartcare plus financial incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: control (standard basic education)
Number of subjects: 0
Study: 23886401

Group type: EXPERIMENTAL
Intervention: Therapist-supported internet-based intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Face-to-face intervention
Number of subjects: 62
Study: 22666758

Group type: EXPERIMENTAL
Intervention: Dorsal root ganglion destruction by adriamycin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Injection (control group)
Number of subjects: 72
Study: 19913781

Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral therapy (CBT)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Online problem-solving therapy (PST)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 263
Study: 18076238

Group type: EXPERIMENTAL
Intervention: Light-load squat intervention set (40% of 1RM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heavy-load squat intervention set (80% of 1RM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study: 16364838

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Bendroflumethiazide 2.5 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg/day (for resistant hypertension)
Number of subjects: 69
Study: 11850256

Group type: EXPERIMENTAL
Intervention: Caspofungin 5 to 100 mg (single-dose)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Caspofungin 15 mg daily (multiple-dose)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Caspofungin 50 mg daily (multiple-dose)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg daily (multiple-dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Caspofungin 50 mg daily without loading dose (multiple-dose)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg daily (3-week study)
Number of subjects: 34
Study: 10592855

Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Mesigyna
Number of subjects: 2252
Study: 8572837

Group type: EXPERIMENTAL
Intervention: 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study: 1956528

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution 2 (CE2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flavored water placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte solution 1 (CE1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 6129886

Group type: EXPERIMENTAL
Intervention: Non-selective beta-adrenoceptor blocker propranolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Selective beta-adrenoceptor blocker metoprolol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 17
Study: 31248962

Group type: EXPERIMENTAL
Intervention: Suprasternal palpation of the ETT tip
Number of subjects: 118

Group type: COMPARATOR
Intervention: Weight-based estimation (insertion depth (cm)=6 + wt (kg))
Number of subjects: 118
Study: 31050931

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment
Number of subjects: 40
Study: 28941948

Group type: EXPERIMENTAL
Intervention: 8-week inter-donation interval (men)
Number of subjects: 45042

Group type: EXPERIMENTAL
Intervention: 10-week inter-donation interval (men)
Number of subjects: 45042

Group type: EXPERIMENTAL
Intervention: 12-week inter-donation interval (women)
Number of subjects: 45042

Group type: EXPERIMENTAL
Intervention: 14-week inter-donation interval (women)
Number of subjects: 45042

Group type: COMPARATOR
Intervention: More frequent donation (compared to standard frequency groups)
Number of subjects: 45042

Group type: COMPARATOR
Intervention: Standard frequency groups (12-week for men, 16-week for women)
Number of subjects: 45042
Study: 26049533

Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Take-home booklet intervention
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Electronic interactive tablet intervention
Number of subjects: 494

Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 494
Study: 24680587

Group type: EXPERIMENTAL
Intervention: BMI <25
Number of subjects: 2596

Group type: EXPERIMENTAL
Intervention: BMI ≥40
Number of subjects: 2596

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 2596

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2596

Group type: EXPERIMENTAL
Intervention: Race
Number of subjects: 2596

Group type: EXPERIMENTAL
Intervention: Risk group
Number of subjects: 2596